Stage III Verrucous Carcinoma of the Larynx Completed Phase 1 / 2 Trials for DB00112 (Bevacizumab)

IndicationStatusPhase
DBCOND0029516 (Stage III Verrucous Carcinoma of the Larynx)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101348Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerTreatment